scAAV9 U7 ACCA
Alternative Names: scAAV9.U7.ACCALatest Information Update: 08 Apr 2021
At a glance
- Originator Audentes Therapeutics
- Developer Astellas Gene Therapies; Nationwide Children's Hospital
- Class Gene therapies; Small interfering RNA
- Mechanism of Action Dystrophin expression stimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Duchenne muscular dystrophy
Most Recent Events
- 01 Apr 2021 Audentes Therapeutics is now called Astellas Gene Therapies
- 07 Feb 2020 Phase-I/II clinical trials in Duchenne muscular dystrophy (In infants, In children) in USA (Parenteral) (NCT04240314)
- 07 Feb 2020 Preclinical data for Duchenne muscular dystrophy released by Audentes Therapeutics (NCT04240314)